Clinical Trial Update: An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for guselkumab (CNTO1959) in generalized pustular psoriasis and erythrodermic psoriasis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erythrodermic Psoriasis
• Pustular Psoriasis

Drugs mentioned

• Guselkumab (guselkumab)

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Pustular Psoriasis | Phase 3 | Status: COMPLETED